Trial · NCT06868667
Adverse events318
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 318
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Malaise | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 4 | 10 | 4 |
| other | Malaise | General disorders | Daratumumab + Bor + Dex | 3 | 14 | 3 |
| other | Pyrexia | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 2 | 10 | 2 |
| other | Pyrexia | General disorders | Daratumumab + Bor + Dex | 4 | 14 | 5 |
| other | Injection site erythema | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 3 | 10 | 3 |
| other | Injection site erythema | General disorders | Daratumumab + Bor + Dex | 2 | 14 | 2 |
| other | Sensation of foreign body | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 3 | 10 | 7 |
| other | Sensation of foreign body | General disorders | Daratumumab + Bor + Dex | 0 | 14 | 0 |
| other | Infusion site erythema | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 0 | 10 | 0 |
| other | Infusion site erythema | General disorders | Daratumumab + Bor + Dex | 2 | 14 | 2 |
| other | Fatigue | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 0 | 10 | 0 |
| other | Fatigue | General disorders | Daratumumab + Bor + Dex | 1 | 14 | 1 |
| other | Injection site reaction | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 0 | 10 | 0 |
| other | Injection site reaction | General disorders | Daratumumab + Bor + Dex | 1 | 14 | 1 |
| other | Non-cardiac chest pain | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 1 | 10 | 1 |
| other | Non-cardiac chest pain | General disorders | Daratumumab + Bor + Dex | 0 | 14 | 0 |
| other | Oedema | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 0 | 10 | 0 |
| other | Oedema | General disorders | Daratumumab + Bor + Dex | 1 | 14 | 1 |
| other | Oedema peripheral | General disorders | Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) | 1 | 10 | 1 |
| other | Oedema peripheral | General disorders | Daratumumab + Bor + Dex | 0 | 14 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06868667/events